Patents by Inventor Marshall Z. Schwartz

Marshall Z. Schwartz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7074764
    Abstract: The present invention relates to a method and composition for treating a patient having a condition characterized as inflammatory bowel disease with an effective dose of HGF. Inflammatory bowel disease as defined by the present invention, includes Chronic Ulcerative Colitis, Crohn's Disease, necrotizing enterocolitis, severe acute gastroenteritis, chronic gastroenteritis, cholera, chronic infections of the bowel, immunologic disorders affecting the intestine, immunodeficiency syndromes affecting the intestine, and HIV. Mucosal damage and histologic lesions are reduced by administering an effective dose of HGF to patients suffering from the same. Specifically, the effective dose of HGF is in a range of about 30 ?g/kg body weight/day to about 300 ?g/kg body weight/day. HGF may be administered to the patient lumenally or systemically.
    Type: Grant
    Filed: August 17, 2001
    Date of Patent: July 11, 2006
    Assignee: The Nemours Foundation
    Inventor: Marshall Z. Schwartz
  • Publication number: 20020013265
    Abstract: The present invention relates to a method and composition for treating a patient having a condition characterized as inflammatory bowel disease with an effective dose of HGF. Mucosal damage and histologic lesions are reduced by administering HGF to patients suffering from the same. HGF may be administered to the patient lumenally or systemically.
    Type: Application
    Filed: August 17, 2001
    Publication date: January 31, 2002
    Inventor: Marshall Z. Schwartz
  • Patent number: 6319899
    Abstract: The present invention relates to a method and composition for treating a patient having a condition characterized as inflammatory bowel disease with an effective dose of HGF. Mucosal damage and histologic lesions are reduced by administering HGF to patients suffering from the same. HGF may be administered to the patient lumenally or systemically.
    Type: Grant
    Filed: September 14, 1999
    Date of Patent: November 20, 2001
    Assignee: The Nemours Foundation
    Inventor: Marshall Z. Schwartz
  • Patent number: 5972887
    Abstract: Reversal of reduced intestinal mucosal mass and absorptive function in patients by the administration of low doses of exogenous HGF either systemically or intraluminally.
    Type: Grant
    Filed: September 17, 1997
    Date of Patent: October 26, 1999
    Assignee: The Nemours Foundation
    Inventor: Marshall Z. Schwartz